Pathstone Holdings
IONS icon

Pathstone Holdings’s Ionis Pharmaceuticals IONS Stock Holding History

Pathstone Holdings’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.7M Buy
34,004
+1,169
+4% +$88K 0.01% 951
2026
Q1 		$2.47M Sell
32,835
-1,469
-4% -$116K 0.01% 916
2025
Q4 		$2.71M Buy
34,304
+702
+2% +$52.9K 0.01% 869
2025
Q3 		$2.2M Buy
33,602
+2,843
+9% +$139K 0.01% 965
2025
Q2 		$1.22M Sell
30,759
-3,613
-11% -$118K ﹤0.01% 1290
2025
Q1 		$1.03M Buy
34,372
+8,314
+32% +$272K ﹤0.01% 1374
2024
Q4 		$911K Sell
26,058
-1,749
-6% -$65.4K ﹤0.01% 1415
2024
Q3 		$1.11M Buy
27,807
+5,102
+22% +$237K ﹤0.01% 1309
2024
Q2 		$1.08M Buy
22,705
+1,452
+7% +$59.6K ﹤0.01% 1286
2024
Q1 		$921K Buy
21,253
+9,371
+79% +$447K ﹤0.01% 1324
2023
Q4 		$611K Buy
+11,882
New +$569K ﹤0.01% 1378

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Pathstone Holdings's IONS Position: Q2 2026 in Review

Pathstone Holdings increased its Ionis Pharmaceuticals (IONS) stake by 3.6% in Q2 2026, buying an estimated $88K and bringing the position to 34,004 shares worth $2.7M. The position accounts for 0.01% of the portfolio, ranked #951.

Pathstone Holdings first reported a position in IONS in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.71M in Q4 2025. 513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Pathstone Holdings held 34,004 shares of Ionis Pharmaceuticals worth $2.7M as of Q2 2026.
  • Pathstone Holdings bought 1,169 Ionis Pharmaceuticals shares in Q2 2026, an estimated $88K.
  • Ionis Pharmaceuticals made up 0.01% of Pathstone Holdings's portfolio in Q2 2026, its #951 holding.
  • Pathstone Holdings first reported a position in Ionis Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Pathstone Holdings's Ionis Pharmaceuticals position peaked at $2.71M in Q4 2025.
  • 513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.